EUVIMEDEUVIMED entdecken
Crossref

Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome

Wan-Ru Yu, Tsung-Cheng Hsieh, Ya-Hui Wu, Hann-Chorng Kuo iD

LUTS: Lower Urinary Tract Symptoms · 2026-03 · 18 (2)

DOI: 10.1111/luts.70057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, online erschienen am 14.03.2026. Verfasst von Wan-Ru Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Cystitis, Interstitial, Platelet-Rich Plasma, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Buddhist Tzu Chi Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To estimate response to intravesical onabotulinumtoxinA (BoNT‐A) injection and platelet‐rich plasma (PRP) therapy in females with bladder pain syndrome (BPS) without Hunner lesions, we developed and internally validated treatment‐specific predictive models integrating clinical characteristics, bladder functional parameters, and urinary biomarkers. Materials and Methods Females with BPS who underwent intravesical BoNT‐A injection or PRP therapy were retrospectively analyzed. A total of 273 female patients were included in the final analysis. Multivariable logistic regression models were constructed to predict treatment response, defined as a Global Response Assessment score ≥ 2. Model discrimination was assessed using the area under the receiver operating characteristic (ROC) curve. For interpretability, nomogram visualizations and a conceptual framework are provided in the .

Results

The BoNT‐A model demonstrated acceptable discrimination (area under the ROC curve: 0.789), whereas the PRP model showed superior discriminatory performance (area under the ROC curve: 0.895). Distinct clinical features and biomarker patterns contributed to each treatment‐specific model, suggesting differential underlying mechanisms. Internal validation revealed higher observed response rates when the administered therapy matched the model‐predicted higher probability of response, supporting internal model concordance.

Conclusions

Treatment‐specific models combining clinical, urodynamic, and urinary biomarker data provide mechanistic insight into heterogeneous response profiles to BoNT‐A and PRP in females with BPS. While these models may inform future phenotype‐guided research and prospective validation, external validation is required before broader clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ACystitis, InterstitialPlatelet-Rich PlasmaNeuromuscular AgentsHumansFemaleBiomarkersRetrospective StudiesAdministration, IntravesicalMiddle AgedTreatment OutcomeAdultROC Curve

Stichwörter der Autor:innen

interstitial cystitispredictive modelingurinary biomarkers

Substanzen

Botulinum Toxins, Type ABiomarkersonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Nursing, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.
  • Department of Nursing, Tzu Chi University, Hualien, Taiwan.
  • Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
  • Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan.

ORCID-Profile: Hann-Chorng Kuo

Förderung

  • Buddhist Tzu Chi Medical Foundation

Zitieren

APA

Yu, W. R., Hsieh, T. C., Wu, Y. H., & Kuo, H. C. (2026). Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome. LUTS: Lower Urinary Tract Symptoms, 18(2). https://doi.org/10.1111/luts.70057

Vancouver

Yu WR, Hsieh TC, Wu YH, Kuo HC. Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome. LUTS: Lower Urinary Tract Symptoms. 2026;18(2). doi:10.1111/luts.70057

BibTeX
@article{Yu2026,
  author = {Yu, Wan-Ru and Hsieh, Tsung-Cheng and Wu, Ya-Hui and Kuo, Hann-Chorng},
  title = {Treatment‐Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet‐Rich Plasma in Bladder Pain Syndrome},
  journal = {LUTS: Lower Urinary Tract Symptoms},
  year = {2026},
  volume = {18},
  number = {2},
  doi = {10.1111/luts.70057}
}
Kostenlos starten →